IP
SGMO

Isthmus Partners’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Isthmus Partners’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-9,328
Closed -$351K – 197
2019
Q1 		$351K Buy
+9,328
New +$95.3K 0.09% 122
2018
Q4 		– Sell
-100
Closed -$2K – 260
2018
Q3 		$2K Hold
100
– – ﹤0.01% 277
2018
Q2 		$1K Hold
100
– – ﹤0.01% 266
2018
Q1 		$2K Hold
100
– – ﹤0.01% 263
2017
Q4 		$2K Buy
+100
New +$1.49K ﹤0.01% 287

Other funds holding SGMO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Isthmus Partners's SGMO Position: Q2 2019 in Review

Isthmus Partners sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2019, closing a stake of 9,328 shares — an estimated $351K sold.

Isthmus Partners first reported a position in SGMO in Q4 2017 and held it in 5 quarters. The position peaked at $351K in Q1 2019. 185 funds tracked by Wall St. Rank hold SGMO as of Q2 2019.

  • Isthmus Partners reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2019 after selling out during the quarter.
  • Isthmus Partners sold 9,328 SANGAMO THERAPEUTICS INC shares in Q2 2019, an estimated $351K.
  • Isthmus Partners first reported a position in SANGAMO THERAPEUTICS INC in Q4 2017 and held it in 5 quarters.
  • Isthmus Partners's SANGAMO THERAPEUTICS INC position peaked at $351K in Q1 2019.
  • 185 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2019.

Based on Isthmus Partners's 13F filing for Q2 2019, filed 9 Aug 2019.